Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

101 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.
Luke JJ, Rutkowski P, Queirolo P, Del Vecchio M, Mackiewicz J, Chiarion-Sileni V, de la Cruz Merino L, Khattak MA, Schadendorf D, Long GV, Ascierto PA, Mandala M, De Galitiis F, Haydon A, Dummer R, Grob JJ, Robert C, Carlino MS, Mohr P, Poklepovic A, Sondak VK, Scolyer RA, Kirkwood JM, Chen K, Diede SJ, Ahsan S, Ibrahim N, Eggermont AMM; KEYNOTE-716 Investigators. Luke JJ, et al. Among authors: poklepovic a. Lancet. 2022 Apr 30;399(10336):1718-1729. doi: 10.1016/S0140-6736(22)00562-1. Epub 2022 Apr 1. Lancet. 2022. PMID: 35367007 Clinical Trial.
Multiple Immunotherapy-Related Cardiovascular Sequelae.
Menachery SM, Chuquin D, Sindel A, Poklepovic A, Abbate A, Bottinor W. Menachery SM, et al. Among authors: poklepovic a. CJC Open. 2022 Nov 29;5(2):170-172. doi: 10.1016/j.cjco.2022.11.018. eCollection 2023 Feb. CJC Open. 2022. PMID: 36880070 Free PMC article. No abstract available.
HDAC inhibitors enhance the immunotherapy response of melanoma cells.
Booth L, Roberts JL, Poklepovic A, Kirkwood J, Dent P. Booth L, et al. Among authors: poklepovic a. Oncotarget. 2017 May 17;8(47):83155-83170. doi: 10.18632/oncotarget.17950. eCollection 2017 Oct 10. Oncotarget. 2017. PMID: 29137331 Free PMC article.
The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib.
Booth L, Roberts JL, Poklepovic A, Kirkwood J, Sander C, Avogadri-Connors F, Cutler RE Jr, Lalani AS, Dent P. Booth L, et al. Among authors: poklepovic a. Cancer Biol Ther. 2018 Feb 1;19(2):132-137. doi: 10.1080/15384047.2017.1394556. Epub 2017 Dec 8. Cancer Biol Ther. 2018. PMID: 29219657 Free PMC article.
101 results